HOOK vs. GRTS, NTGN, ME, RVNC, CRMD, XOMA, MRSN, VNDA, XERS, and EPIX
Should you be buying Hookipa Pharma stock or one of its competitors? The main competitors of Hookipa Pharma include Gritstone bio (GRTS), Neon Therapeutics (NTGN), 23andMe (ME), Revance Therapeutics (RVNC), CorMedix (CRMD), XOMA (XOMA), Mersana Therapeutics (MRSN), Vanda Pharmaceuticals (VNDA), Xeris Biopharma (XERS), and ESSA Pharma (EPIX). These companies are all part of the "medical" sector.
Gritstone bio (NASDAQ:GRTS) and Hookipa Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, community ranking, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.
In the previous week, Gritstone bio and Gritstone bio both had 4 articles in the media. Hookipa Pharma's average media sentiment score of 0.72 beat Gritstone bio's score of 0.70 indicating that Gritstone bio is being referred to more favorably in the media.
Gritstone bio received 55 more outperform votes than Hookipa Pharma when rated by MarketBeat users. Likewise, 69.46% of users gave Gritstone bio an outperform vote while only 69.35% of users gave Hookipa Pharma an outperform vote.
Hookipa Pharma has a net margin of -88.73% compared to Hookipa Pharma's net margin of -926.13%. Gritstone bio's return on equity of -33.33% beat Hookipa Pharma's return on equity.
Hookipa Pharma has higher revenue and earnings than Gritstone bio. Hookipa Pharma is trading at a lower price-to-earnings ratio than Gritstone bio, indicating that it is currently the more affordable of the two stocks.
Gritstone bio has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Hookipa Pharma has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.
Gritstone bio presently has a consensus target price of $4.75, suggesting a potential upside of 513.93%. Hookipa Pharma has a consensus target price of $4.67, suggesting a potential upside of 487.74%. Given Hookipa Pharma's higher possible upside, analysts clearly believe Gritstone bio is more favorable than Hookipa Pharma.
48.5% of Gritstone bio shares are held by institutional investors. Comparatively, 63.9% of Hookipa Pharma shares are held by institutional investors. 4.6% of Gritstone bio shares are held by insiders. Comparatively, 3.3% of Hookipa Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Gritstone bio and Hookipa Pharma tied by winning 8 of the 16 factors compared between the two stocks.
Get Hookipa Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HOOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hookipa Pharma Competitors List
Related Companies and Tools
